← Back to Search

Insight study cohort for Metabolic Syndrome (METPROS Trial)

N/A
Waitlist Available
Led By Rodrigo Fernández-Verdejo, PhD
Research Sponsored by Pennington Biomedical Research Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Individuals who participated in the InSight study at Pennington Biomedical in 2008-2009.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline (in 2008-2009) and after approximately 16 years (2024-2025)
Awards & highlights
No Placebo-Only Group

Summary

Metabolic flexibility is the capacity to adapt fuel oxidation to fuel availability so that ATP synthesis can match its cellular demands. Thus, for example, increases in glucose availability after a meal would increase glucose oxidation, while increases in lipid availability during fasting would increase lipid oxidation. Enhanced metabolic flexibility has been proposed to protect humans from metabolic diseases. Nevertheless, most studies examining associations between metabolic flexibility and metabolic health outcomes have used cross-sectional designs. Whether impaired metabolic flexibility causes or results from metabolic health impairment is thus unclear. In this study, the investigators will use the data from a study conducted approximately 16 years ago in healthy participants without obesity. Using the data already collected in that study, the metabolic flexibility of each participant will be calculated. To test the association between metabolic flexibility and the change in metabolic health, the investigators will call back all the participants for a single follow-up visit to reassess several metabolic health outcomes. Thus, the main aim of the study is to test the association between metabolic flexibility and the change in metabolic health outcomes after 16 years in humans.

Eligible Conditions
  • Metabolic Syndrome
  • Obesity

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline (in 2008-2009) and after approximately 16 years (2024-2025)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline (in 2008-2009) and after approximately 16 years (2024-2025) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood pressure
Body fat percentage
Body mass index
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Insight study cohortExperimental Treatment3 Interventions
The proposed study will include the individuals who participated in the baseline assessment of the InSight study at Pennington Biomedical in 2008-2009. These participants were not subjected to any intervention.

Find a Location

Who is running the clinical trial?

Pennington Biomedical Research CenterLead Sponsor
309 Previous Clinical Trials
180,044 Total Patients Enrolled
4 Trials studying Metabolic Syndrome
177 Patients Enrolled for Metabolic Syndrome
Rodrigo Fernández-Verdejo, PhDPrincipal InvestigatorPennington Biomedical Research Center
Eric Ravussin, PhDPrincipal InvestigatorPennington Biomedical Research Center
12 Previous Clinical Trials
397 Total Patients Enrolled
1 Trials studying Metabolic Syndrome
63 Patients Enrolled for Metabolic Syndrome
~59 spots leftby Apr 2025